653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Novel Targets and Amyloid
Suzanne Trudel, Adam D Cohen, Amrita Y. Krishnan, et al.
Cevostamab Mono continues to have clinically meaningful activity in heavily pretreated RRMM with a target dose-dependent increase in the ORR, but not an increase in the CRS rate. Persistent reactions are seen in patients with prior exposure to CAR-Ts, BsAbs, and ADCs. Compared to the SS dosage, the DS dosage at the 0.3 / 3.6 mg level appears to be associated with a trend towards an improved C1 safety profile.
Amrita Y. Krishnan, Monique C. Minnema, Jesús G. Berdeja, et al.
SC-talquetamab is well tolerated and highly effective in both RP2Ds. Rarer, higher doses of SC talquetamab (in the 800 µg / kg biweekly cohorts) did not negatively affect the safety profile described above.
Raymond Comenzo, Giovanni Palladini, Efstathios Kastritis, et al.
D-VCd has persistent clinical advantages over VCd in terms of haematological response and organ responses upon prolonged follow-up. However, it should be noted that many patients in the D-VCd arm received daratumumab monotherapy after 6 cycles of D-VCd. The patients in the VCd group, however, discontinued study treatment. Despite everything, the study continues to support the use of D-VCd versus VCd alone in newly diagnosed AL amyloidosis. D-VCd has now been approved and represents a new SOC for patients with AL amyloidosis.
Jeffrey A. Zonder, Joshua Richter, Naresh Bumma, et al.
REGN5458 further demonstrates an acceptable safety and tolerability profile with Gr 2 CRS in only 4.4% of patients and without Gr ≥ 3 CRS or neurotoxicity events. No new safety signals were observed. In multiple refractory patients with RRMM, an early, profound and sustained response rate of 73.3% was observed with the combined doses (96 & 200 mg).
Ajai Chari, Parameswaran Hari, Nizar J. Bahlis, et al.
Talazoparib plus daratumumab were well tolerated. The safety profile was comparable to that of the monotherapies. The combination showed promising efficacy in RRMM. The further clinical development of the combination therapy talazoparib plus daratumumab is therefore justified.
Sagar Lonial, Rakesh Popat, Cyrille Hulin, et al.
IBER + DEX showed promising and generally well-tolerated efficacy in heavily pretreated, triple exposed and refractory RRMM as well as when anti-BCMA therapy was administered beforehand; TEAEs could be managed with dose reductions and interruptions. This study supports the further development of IBER in MM, including phase 3 studies in combination therapies.